Lung Carcinoma Clinical Trials

25 recruiting

Lung Carcinoma Trials at a Glance

60 actively recruiting trials for lung carcinoma are listed on ClinicalTrialsFinder across 6 cities in 29 countries. The largest study group is Not Applicable with 21 trials, with the heaviest enrollment activity in Houston, Barcelona, and Chicago. Lead sponsors running lung carcinoma studies include M.D. Anderson Cancer Center, Mayo Clinic, and Boehringer Ingelheim.

Browse lung carcinoma trials by phase

Treatments under study

About Lung Carcinoma Clinical Trials

Looking for clinical trials for Lung Carcinoma? There are currently 25 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lung Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lung Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 60 trials

Recruiting
Not Applicable

The Vanguard Study: Testing a New Way to Screen for Cancer

Breast CarcinomaOvarian CarcinomaBladder Carcinoma+8 more
National Cancer Institute (NCI)24,000 enrolled37 locationsNCT06995898
Recruiting
Not Applicable

Novel INPUT Screening Tool to Improve Illness Understanding in Patients With Metastatic or Incurable Lung Cancer

Lung CarcinomaStage IV Lung Cancer AJCC v8Metastatic Lung Carcinoma
M.D. Anderson Cancer Center100 enrolled1 locationNCT06743308
Recruiting
Phase 1

A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3
Boehringer Ingelheim300 enrolled12 locationsNCT04429087
Recruiting
Phase 2

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Neuroendocrine NeoplasmsSmall Cell Lung CarcinomaExtra-pulmonary Neuroendocrine Carcinoma
Boehringer Ingelheim204 enrolled59 locationsNCT05882058
Recruiting
Phase 3

Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.

Small Cell Lung Carcinoma
AstraZeneca70 enrolled15 locationsNCT06992609
Recruiting
Phase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Advanced Colorectal CarcinomaAdvanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+41 more
Mayo Clinic220 enrolled2 locationsNCT05969860
Recruiting
Phase 2

Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial

Lung CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8+10 more
M.D. Anderson Cancer Center50 enrolled1 locationNCT04789681
Recruiting
Not Applicable

Walking After Surgery to Improve Recovery and Outcomes After Surgery, AIRTECH Study

Lung Carcinoma
M.D. Anderson Cancer Center240 enrolled1 locationNCT04783168
Recruiting
Not Applicable

Educating Smokers About Lung Cancer Screening Using Tobacco Quitlines

Lung Carcinoma
M.D. Anderson Cancer Center800 enrolled1 locationNCT04595422
Recruiting
Phase 1Phase 2

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

Small Cell Lung Carcinoma
Merck Sharp & Dohme LLC110 enrolled48 locationsNCT04938817
Recruiting
Phase 1Phase 2

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.118 enrolled4 locationsNCT07407933
Recruiting
Not Applicable

Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaStage IV Lung Cancer AJCC v8+2 more
Mayo Clinic5 enrolled1 locationNCT05746325
Recruiting

NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations

Non-squamous Metastatic Non-Small-Cell Lung Carcinoma
AstraZeneca600 enrolled23 locationsNCT06494540
Recruiting
Not Applicable

New York Better Breathing Study

Stage III Lung Cancer AJCC v8Stage II Lung Cancer AJCC v8Localized Lung Carcinoma+1 more
Roswell Park Cancer Institute100 enrolled1 locationNCT06869447
Recruiting
Phase 3

Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial

Small Cell Lung Carcinoma
Instituto de Investigación Biomédica de Salamanca300 enrolled13 locationsNCT07015892
Recruiting
Not Applicable

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

ALK+ Non-Small-Cell Lung Carcinoma
Pfizer90 enrolled4 locationsNCT06487078
Recruiting
Phase 1

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Large Cell Neuroendocrine Carcinoma of the LungSmall Cell Lung CarcinomaNeuroendocrine Prostate Cancer+1 more
Novartis Pharmaceuticals116 enrolled5 locationsNCT07006727
Recruiting
Phase 2

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Nonsmall Cell Lung Cancer Stage IIIUnresectable Non-Small Cell Lung CarcinomaNonsmall Cell Lung Cancer, Stage II
Wake Forest University Health Sciences28 enrolled1 locationNCT05696782
Recruiting
Not Applicable

CONNECTing to LungCare

Lung CarcinomaSmoking CessationCigarette Smoking-Related Carcinoma
University of California, San Francisco147 enrolled1 locationNCT06213532
Recruiting
Not Applicable

Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers

Lung Carcinoma
City of Hope Medical Center382 enrolled16 locationsNCT06196008